The test is the latest of several Alzheimer's biomarker panels developed on Rules-Based Medicine's DiscoveryMAP platform. The company plans to develop a specialized assay for research use by next year with a lab-developed test potentially following shortly thereafter.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.